{"pub": "morningstar", "url": "https://morningstar.com/news/dow-jones/2019093010075/4d-molecular-therapeutics-files-for-ipo-applies-to-list-on-nasdaq", "downloaded_at": "2019-10-01 00:08:55.623627+00:00", "title": "4D Molecular Therapeutics Files for IPO, Applies to List on Nasdaq", "language": "en", "text": "By Josh Beckerman\n\n4D Molecular Therapeutics Inc., a developer of gene-therapy products, has filed for an initial public offering.\n\nViking Global Investors, which led a $90 million Series B financing round last year, owns a 16% stake. Pfizer Inc. (PFE) owns 11.8%.\n\n4D Molecular, based in Emeryville, Calif., has applied to list on the Nasdaq Global Market under symbol DDDD. The filing lists a placeholder figure of $100 million.\n\nWrite to Josh Beckerman at josh.beckerman@wsj.com\n\n(END) Dow Jones Newswires\n\nSeptember 30, 2019 19:40 ET (23:40 GMT)\n\nCopyright (c) 2019 Dow Jones & Company, Inc.", "description": "", "authors": [], "top_image": "https://morningstar.com/assets/img/30241a1.png", "published_at": "2019-09-30"}